Trials / Completed
CompletedNCT01131208
Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
Gene Expression Profiling Using Paraffin-embedded Tissues and the Nuclease Protection Assay in Diffuse Large B-cell Lymphoma (DLBCL) Treated With CHOP or R-CHOP: An ECOG and SWOG Correlative Study of E4494
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- ECOG-ACRIN Cancer Research Group · Network
- Sex
- All
- Age
- 60 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with diffuse large B-cell lymphoma treated with combination chemotherapy with or without rituximab.
Detailed description
OBJECTIVES: * To identify genes predictive of clinical outcome (failure-free survival and overall survival) among patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP induction on ECOG-E4494 using the nuclease protection assay for measuring gene expression in paraffin-embedded tissue. * To identify genes that change their prognostic profile with the addition of rituximab to CHOP chemotherapy. OUTLINE: This is a multicenter study. Unstained formalin-fixed, paraffin-embedded samples are analyzed for gene expression via nuclease protection assay.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | gene expression analysis | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2010-04-21
- Primary completion
- 2010-08-21
- Completion
- 2010-08-21
- First posted
- 2010-05-26
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT01131208. Inclusion in this directory is not an endorsement.